Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.62 |
| ▸ | RAB9A | P51151 | 5/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | HPGD | P15428 | 4/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.59 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 2/20 | 0.53 |
| ▸ | CA2 | P00918 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | CASP1 | P29466 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7338663 | 0.92 | TSHR (0.65) | POLBRAB9AALDH1A1HPGDNPC1 | |
| SCHEMBL11815924 | 0.85 | POLB (0.60) | POLBRAB9AALDH1A1HPGDNPC1 | |
| Hydrochloric Acid SCHEMBL1624734 | 0.85 | ALDH1A1 (0.64) | POLBRAB9AALDH1A1HPGDNPC1 | |
| SCHEMBL6380991 | 0.84 | POLB (0.58) | POLBRAB9AALDH1A1HPGDNPC1 | |
| SCHEMBL23310021 | 0.83 | POLB (0.66) | POLBRAB9AALDH1A1HPGDNPC1 | |
| SCHEMBL4035087 | 0.83 | POLB (0.65) | POLBRAB9AALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL3136136 | 0.82 | POLB (0.68) | POLBRAB9AALDH1A1HPGDNPC1 | |
| Water SCHEMBL9248793 | 0.81 | POLB (0.63) | POLBRAB9AALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL1372423 | 0.81 | POLB (0.63) | POLBALDH1A1HPGDMAPTKDM4E | |
| SCHEMBL16166399 | 0.81 | POLB (0.56) | POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1594497-B1 | SULFHYDANTOINS AS PHOSPHATE ISOSTERES FOR USE AS PHOSPHATASE INHIBITORS IN THE TREATMENT OF CANCER AND AUTOIMMUNE DISORDERS | VERTEX PHARMA (US) | 2009-05-27 | — | — | EP | disclosed |
| US-7432292-B2 | Sulfhydantoins as phosphate isosteres | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432292-B2 | Sulfhydantoins as phosphate isosteres | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-10-07 | — | — | US | disclosed |
| EP-1594497-A1 | SULFHYDANTOINS AS PHOSPHATE ISOSTERES FOR USE AS PHOSPHATASE INHIBITORS IN THE TREATMENT OF CANCER AND AUTOIMMUNE DISORDERS | Vertex Pharmaceuticals Incorporated (US) | 2005-11-16 | — | — | EP | disclosed |
| US-20040167187-A1 | Sulfhydantoins as phosphate isosteres | VERTEX PHARMACEUTICALS INCORPORATED | 2004-08-26 | — | — | US | disclosed |
| WO-2004062664-A1 | SULFHYDANTOINS AS PHOSPHATE ISOSTERES FOR USE AS PHOSPHATASE INHIBITORS IN THE TREATMENT OF CANCER AND AUTOIMMUNE DISORDERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167187-A1 | Sulfhydantoins as phosphate isosteres | PTPN2, PTPRS, DUSP2 | POLB 4610/4885RAB9A 2071/4885ALDH1A1 2653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.